Coursera Spring Sale
40% Off Coursera Plus Annual!
Grab it
Explore plasma proteomic biomarkers that predict response and resistance to immune checkpoint blockade therapy in melanoma patients through this 16-minute webinar presented by Dr. Russell W. Jenkins. Learn about the critical need for early non-invasive biomarkers since most patients treated with immune checkpoint blockade do not achieve durable treatment responses. Discover cutting-edge research methodologies for identifying proteomic signatures in plasma samples that can help clinicians predict which melanoma patients are most likely to benefit from immunotherapy treatments. Gain insights into the molecular mechanisms underlying treatment resistance and response patterns in immune checkpoint inhibitor therapy. Understand how plasma-based biomarker discovery could revolutionize personalized treatment approaches for melanoma patients and improve clinical decision-making in oncology practice.
